Quick context
Survodutide
Is being studied in phase 3 for body weight and metabolic liver disease.
Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.
Back to all 64 profiles
Clinical researchIn clinical researchWADA
Community protocol · Survodutide
Survodutide: community information and evidence, clearly separated.
A complete substance profile covering documented community themes, scientific context and explicit safety boundaries. Missing or non-standardised data are not replaced with estimates.
Also known as: BI 456906 · GLP-1/glucagon
Sources checked: 27 August 2026
Important safety and liability notice
This page documents and evaluates online community information. It is not medical or therapeutic advice, individual counselling or an invitation to use Ipamorelin. It is not approved for the uses described here.
No medical, therapeutic or individual recommendation. Information is provided without warranty and used at your own risk. No liability for calculation errors, use, contamination, interactions or consequences.
Amounts, timing and cycles
Clinical research
Published study protocols are research procedures with inclusion and exclusion criteria. They are not instructions for unsupervised use.
Amount status
Trials use protocol-bound amounts and escalation; this does not create a safe community dose.
Profile evidence level: clinical.
Timing
Timing is set by each trial protocol and may differ substantially between studies.
No individual recommendation.
Cycle/duration
Duration is study-specific and ends according to protocol; long-term safety may remain unknown.
No individual recommendation.
External community reference available
The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.
Open community sourceReconstitution and U-100 conversion
Reconstitution calculator
For clearly identified single lyophilised substances, the calculator only shows the arithmetic between vial amount, liquid volume and target amount. It does not check identity, purity, sterility, solubility, stability or solvent suitability. The entered target is not a recommendation.
Reconstitution calculator
Calculates concentration, volume and theoretical U-100 units. The preloaded 200 µg is only the reference page's arithmetic example.
Concentration
3,333.33 µg/ml
Calculated volume
0.06 ml
U-100 units
6 U
Calculated portions per vial
50
Calculation aid, not dosage or use advice. Incorrect inputs, a different syringe scale, measurement error, dead space or unknown vial content produce incorrect results.
Mechanism and research questions
Glucagon and GLP-1 receptor agonist
Survodutide is classified as “Glucagon and GLP-1 receptor agonist”. Is being studied in phase 3 for body weight and metabolic liver disease. This describes the investigated pathway but does not validate a community use, amount, route or combination.
Glucagon/GLP-1 combined action
Researchers test whether combining glucagon and GLP-1 signalling increases energy expenditure in addition to appetite suppression. Liver fat levels and weight trajectory are compared against pure GLP-1 agents.
Body weight and metabolism
Researchers track changes in body weight, body composition, and metabolic markers such as blood sugar or cholesterol over the course of a study. This is similar to following someone's weight and lab values over months to see broader trends rather than day-to-day fluctuations.
Liver and cardiorenal outcomes
This looks at effects on liver fat, heart function, and kidney markers, organs that are closely linked through shared metabolic and blood flow pathways. Studies typically measure liver fat imaging, blood pressure, and kidney function tests over time.
What communities discuss
These themes describe discussion and vendor claims. They do not prove benefit, safety, product identity or suitable use.
Weight management forums
In these forums, users compare their own weight trajectories, side effects, and perceived appetite changes between different products. Before-and-after photos and personal timelines are often shared. Such anecdotes and vendor marketing claims are not scientific proof of efficacy.
Source and purity discussion
Discussion covers which vendors are seen as more trustworthy and how purity test results differ between batches. Such community assessments are based on limited samples and do not replace independent lab testing of each individual batch.
Stack and blend discussion
Users exchange self-assembled combinations of several peptides and compare perceived effects, often without the specific combination ever having been studied. Such stack recommendations are personal opinions, not vetted protocols.
Adverse effects and risk boundaries
- Gastrointestinal effects, dehydration, and changes in glucose or appetite may occur depending on the target; incretin medicines can also carry gallbladder, pancreatic and retinopathy warnings.
- Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
- A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.
Exclusion groups and professional assessment
- Pregnancy, severe gastric-emptying disorders, and relevant pancreatic, gallbladder, renal or endocrine disease require professional assessment; the exact label may add contraindications.
- Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
- Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.
Monitoring and laboratory markers
- Depending on substance and indication, weight, blood pressure, hydration, glucose/HbA1c, kidney and liver markers, and concomitant medicines may be reviewed; symptoms guide further tests.
- Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.
Evidence boundary
In clinical trials
Phase 3 trials are underway; robust long-term results are still pending.
Published evidence
The substance is currently being studied in structured human clinical trials, but a general approval does not yet exist.
Survodutide combines glucagon and GLP-1 activity, unlike pure GLP-1 agonists.
Storage and stability
- The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
- Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
- Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.
Troubleshooting and error sources
- U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
- Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
- Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
- Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.
Regulatory status and WADA
In clinical research
A clinical-development candidate, not an approved medicinal product.
WADA 2026
This profile is marked as WADA-relevant. Check the original 2026 Prohibited List and the specific sport/route; a prohibition may cover an entire class or related agents.
WADA — 2026 Prohibited ListComparisons and related profiles
Combinations / stacks
- Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
- Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
- Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.
Frequently asked questions
Is an amount shown here a recommendation?
No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.
Does the U-100 calculator prove correct use?
No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.
Can this profile be combined with other substances?
Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.
Which source controls when information conflicts?
For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.
Are community claims clinical evidence?
No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.
Sources and evidence layers
Primary sources and official registries take priority. The community reference is labelled separately.
- Primary/technical sourceClinicalTrials.gov — NCT06066515
- Primary/technical sourceWADA — 2026 Prohibited List
- Community referenceSurvodutide — Peptide Dosing Protocols